Compare UNIT & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UNIT | AAPG |
|---|---|---|
| Founded | 2024 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2024 | 2024 |
| Metric | UNIT | AAPG |
|---|---|---|
| Price | $4.01 | $13.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | $7.97 | ★ $44.50 |
| AVG Volume (30 Days) | ★ 5.2M | 5.4K |
| Earning Date | 11-09-2026 | 08-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 660.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,234,500,000.00 | N/A |
| Revenue This Year | $64.79 | $17.91 |
| Revenue Next Year | N/A | $111.96 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 91.49 | N/A |
| 52 Week Low | $3.91 | $13.12 |
| 52 Week High | $12.94 | $33.09 |
| Indicator | UNIT | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 30.08 | 34.59 |
| Support Level | N/A | N/A |
| Resistance Level | $5.55 | $16.28 |
| Average True Range (ATR) | 0.47 | 0.44 |
| MACD | 0.06 | -0.17 |
| Stochastic Oscillator | 3.35 | 0.00 |
Uniti is the product of the August 2025 merger of the firm with Windstream, its former primary customer. The combined firm owns a 240,000 route-mile fiber network that serves enterprise and residential customers. Selling high-capacity fiber circuits to enterprises generates about 25% of consolidated revenue. Uniti's residential networks, housed within its Kinetic business segment, reach about 4.5 million households, mostly in less-populated markets in the Southeast. About 2.2 million of these locations have been upgraded with fiber, and legacy copper-cable networks serve the remainder. Residential services account for about a third of total revenue. Small business and wholesale services provided within the Kinetic service territory account for about 20% of revenue.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.